Literature DB >> 8995343

Venous elasticity after treatment with Daflon 500 mg.

V Ibegbuna1, A N Nicolaides, O Sowade, M Leon, G Geroulakos.   

Abstract

It has been demonstrated that patients predisposed to the development of varicose veins have an abnormal venous tone, and may have symptoms in the absence of obvious varicosities. It has been suggested that venotonic drugs relieve the symptoms of chronic venous insufficiency by decreasing capillary leakage and improving venous tone. The aim of this study was to determine the effect of Daflon 500 mg in patients with abnormal venous elasticity without varicose veins. Twenty-five healthy female volunteers aged 18-35 were included in the study. They presented with symptomatic varicose veins in one leg and an abnormal elastic modulus without varicosities in the opposite leg. Treatment group: 12 patients received 2 tablets of Daflon 500 mg (1000 mg/day); control group: 13 patients received no treatment. The elastic modulus K was determined using the air plethysmograph. Simultaneous measurements of calf volume changes were made in response to different venous pressures produced by a thigh pneumatic cuff. In the control group K (mean +/- sd) was 10.8 x 10(3) +/- 4.1 x 10(3) N/m2 at the beginning and 10.2 x 10(3) +/- 3.1 x 10(3) N/m2 at the end of the study (P > 0.1). In the treatment group the initial K was 10.2 x 10(3) +/- 3.9 x 10(3) N/m2 and 14.2 x 10(3) +/- 5.1 x 10(3) N/m2 at the end (P < 0.02). The results of the Wilcoxon rank sum test indicated that 4 weeks' therapy with Daflon 500 mg is effective in improving venous tone in patients with symptoms but without varicose veins.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995343     DOI: 10.1177/000331979704800108

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  7 in total

Review 1.  Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  How steroid hormones act on the endothelium--insights by atomic force microscopy.

Authors:  Uta Hillebrand; Martin Hausberg; Detlef Lang; Christian Stock; Christoph Riethmüller; Chiara Callies; Eckhart Büssemaker
Journal:  Pflugers Arch       Date:  2008-01-03       Impact factor: 3.657

Review 3.  Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review.

Authors:  Ke Xuan Li; Gisele Diendéré; Jean-Philippe Galanaud; Nada Mahjoub; Susan R Kahn
Journal:  Res Pract Thromb Haemost       Date:  2021-05-08

4.  Factors affecting patients' self-management in chronic venous disorders: a single-center study.

Authors:  Kamil Barański; Jerzy Chudek
Journal:  Patient Prefer Adherence       Date:  2016-08-24       Impact factor: 2.711

Review 5.  Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy.

Authors:  Armando Mansilha; Joel Sousa
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

6.  Conservative Treatment of Hemorrhoids: Results of an Observational Multicenter Study.

Authors:  Evgeny A Zagriadskiĭ; Alexey M Bogomazov; Evgeny B Golovko
Journal:  Adv Ther       Date:  2018-10-01       Impact factor: 3.845

7.  Standard of care for lipedema in the United States.

Authors:  Karen L Herbst; Linda Anne Kahn; Emily Iker; Chuck Ehrlich; Thomas Wright; Lindy McHutchison; Jaime Schwartz; Molly Sleigh; Paula Mc Donahue; Kathleen H Lisson; Tami Faris; Janis Miller; Erik Lontok; Michael S Schwartz; Steven M Dean; John R Bartholomew; Polly Armour; Margarita Correa-Perez; Nicholas Pennings; Edely L Wallace; Ethan Larson
Journal:  Phlebology       Date:  2021-05-28       Impact factor: 1.740

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.